1. Introduction {#sec1}
===============

Cerebrovascular diseases and cardiovascular diseases are among the top three leading causes of death and disability worldwide \[[@B1], [@B2]\]. The mortality rate due to stroke is as high as 276.9/100,000 each year in China \[[@B3]\], which means nearly 400,000 people die of stroke every year. Ischemic stroke (IS) is a complex disorder resulting from the interplay of genetic and environmental factors (such as age, smoking, hypertension, cardiac arrhythmias, and diabetes mellitus) \[[@B4]\]. It has been shown that genetic factors increase the risk of stroke. The risk rate of a person with a family history of stroke is up to 30% \[[@B5]\]. Compared with dizygotic twins, the rates of death and hospitalization due to stroke were increased for monozygotic twins \[[@B6]\].

Present prevention and treatment of stroke are involved in the control of risk factors \[[@B7]\] and revascularization of vascular stenosis. Medical therapy was often effective for preventing stroke. However, some patients may still experience recurrent ischemic stroke in spite of receiving aggressive medical treatment \[[@B8]\]. With the rapid advance of precise medicine, it is of great importance to find and validate biomarkers for the diagnosis, treatment, and prognosis of stroke.

The protein encoded for by the*kalirin gene (KALRN)* is a guanine nucleotide exchange factor (GEF), which has numerous functions, such as neuron morphogenesis \[[@B9], [@B10]\], modifies synphilin-1 aggregate transport \[[@B11]\], and promotes smooth muscle cell (SMC) migration and proliferation \[[@B12]\]. Studies found that*KALRN* gene variations were associated with CHD \[[@B13]--[@B16]\]. As an atherosclerotic disease, stroke may share some genes with coronary heart disease (CHD). A possible association between*KALRN* gene polymorphisms and IS among distinct population remains unknown. Thus, the aim of the present study was to investigate if*KALRN* SNPs were associated with ischemic stroke among Han Chinese.

2. Materials and Methods {#sec2}
========================

2.1. Subjects {#sec2.1}
-------------

A cohort of 747 individuals, including 385 ischemic stroke patients and 362 hypertensive controls without stroke, was included in the present study. The ischemic stroke group was composed of 297 patients found during the epidemiological survey of Fuxin rural areas (Liaoning province, China) \[[@B17]\] and 88 ischemic stroke patients from the First Hospital of China Medical University. The study subjects were unrelated to one another, were all Han Chinese, and were older than 35 years of age. Subjects were excluded if they had a history of hemorrhagic stroke, tumor, trauma, myocardial infarction, or atrial arrhythmia. All IS cases were confirmed to be atherosclerotic ischemic stroke by brain imaging using computed tomography (CT) scanning and/or magnetic resonance imaging (MRI). A diagnosis of IS was confirmed by 2 neurologists.

The control group included unrelated individuals without any history or symptoms of cerebrovascular disease and were matched with the IS patients for residency area, ethnic origin, and gender. Brain imaging was not used for controls. As stroke is a late-onset disease, we selected older people as controls to minimize the chances for misclassification as "stroke-free."

All participants were given a questionnaire that included demographic variables (age, gender, and nationality). Histories of conventional risk factors (hypertension, diabetes mellitus, smoking, and alcohol drinking) were also recorded. Blood pressure (BP) was measured using a standardized automated electronic sphygmomanometer (Omron, Dalian, China). Biochemical analyses were done using an automated enzymatic procedure (AU640, Olympus, Japan) in our central laboratory. After providing informed consent, 5 ml venous blood was obtained from each subject and kept at --20°C until analyzed.

The work has been carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving human subjects. Our procedures were approved by the Ethics Committee of China Medical University, and written informed consent was obtained from all participants.

2.2. SNP Selection and Genotyping {#sec2.2}
---------------------------------

Genomic DNA was isolated from EDTA anticoagulated whole blood of subjects in the laboratory of Shengjing Hospital of China Medical University using blood genomic DNA extraction kits according to the manufacturer\'s protocol (TIANamp Genomic DNA kit, Tiangen Biochemical Technology, Beijing, China) and kept at −20°C until analyzed.

The three selected SNPs for the present study were tag-SNPs selected from HapMap databases: rs7620580 (TTTGCTTGGTAGTGGTTGCATGTGC\[A/G\]TGTGTGCATGTGTGGACTGTCTGCT, Chromosome: 3: 124326456; Functional Consequence: intron variant), rs2289843 (AGGTGACATACATCTGAAATTTGTC\[A/T\]GCCTAAAAAGAACAAAGATAATAAT, Chromosome: 3:  124477247; Functional Consequence: synonymous codon) and rs1708303 (AGAATGGAGGCAAGTCCGAGTCCGT\[A/G\]GCCAACCTGCAGGCCCAGCCCTCCC, Chromosome: 3: 124632469; Functional Consequence: synonymous codon). The SNPs were to cover the genes of interest with an*r*^2^ threshold of 0.8 and minor allele frequency (MAF) greater than 0.1. Genotyping was done using the ligase detection reaction method (LDR-PCR) \[[@B18]--[@B20]\]. Primers were designed with primer 5 and probes were designed by Shanghai Generay Biotech (<http://www.generay.com.cn/>) ([Table 1](#tab1){ref-type="table"}). Allele and genotype frequencies were determined by analyzing the raw data from ABI 3730XL with Peak Scanner Software v1.0 (ABI). About 10% randomly selected samples were genotyped repeatedly to ensure that the results were 100% concordant.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Statistical analyses were done using SPSS (v 13.0) and the SHEsis analysis platform (<http://analysis.bio-x.cn/myAnalysis.php>). Data are presented as mean ± standard deviation (SD) with normal distribution by using the *t*-test. Count data are presented as number of cases and percentage. Pearson Chi-square (*X*^2^) tests or Fisher\'s exact test were used to compare the frequencies of demographic variables and to assess differences in SNP genotypes and alleles between cases and controls. Hardy-Weinberg equilibrium (HWE) was assessed using *X*^2^ tests. Odds ratios (OR) with 95% confidence intervals (CI) were determined using unconditional logistic regression analysis. Multivariate analysis was evaluated by logistic regression models to test the association of gene variation and ischemic stroke risk after adjusting the confounding risk factors. The SHEsis analysis platform was used to calculate linkage disequilibrium indices (*D*′ and*r*^2^) and inferred haplotype frequencies \[[@B21], [@B22]\].

3. Results {#sec3}
==========

3.1. Subject Characteristics {#sec3.1}
----------------------------

The demographic and clinical characteristics of the subjects were shown in [Table 2](#tab2){ref-type="table"}. There were no significant differences between cases and controls for gender, heart rate, or total cholesterol levels. Because we chose cases that were younger than controls, their mean ages were different (62.30 ± 9.75 versus 69.01 ± 7.32 years). As expected, the prevalence of the most common risk factors for atherosclerosis was significantly different between cases and controls: body mass index (BMI) (*p* = 0.006), drinking (*p* = 0.006), smoking (*p* = 0.039), triglyceride (TG) (*p* = 0.006), low density lipid cholesterol (LDL-C) (*p* \< 0.001), high density lipid cholesterol (HDL-C) (*p* \< 0.001), and fasting plasma glucose (FPG) (*p* = 0.035).

3.2. Association between SNPs and Ischemic Stroke Risk {#sec3.2}
------------------------------------------------------

The genotype distributions and allelic frequencies for the 3 SNPs that we selected among cases and controls were shown in Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}. All allele distributions of the studied SNPs were in HWE.

For a dominant model, analyses were done by combining the heterozygous variant genotype with the homozygous variant genotype. For a recessive model, analyses were done by combining the heterozygous variant genotype with the wild type homozygous genotype. As shown in [Table 3](#tab3){ref-type="table"}, SNP rs7620580 (dominant model: OR = 1.590 (95% CI 1.187--2.130), *p* = 0.002; additive model: OR = 1.490 (95% CI 1.157--1.919), *p* = 0.002) and SNP rs1708303 (dominant model: OR = 1.523 (95% CI 1.119--2.073), *p* = 0.007; additive model: OR = 1.438 (95% CI 1.092--1.892), *p* = 0.01) were significantly associated with ischemic stroke in this population. The GG genotype and G allele of SNP rs7620580 were associated with a risk for ischemic stroke with an adjusted OR of 3.195 (95% CI 1.228--8.312, *p* = 0.017) and OR of 1.446 (95% CI 1.136--1.841, *p* = 0.003), respectively (Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}). However, there were no significant differences in the allele and genotype distributions for SNP rs2289843 between cases and controls in total subjects.

Because some conventional confounding risk factors may also contribute to the development of stroke, we analyzed the associations between these SNPs and IS after adjusting for these factors. Multivariate logistic regression analysis showed that, after adjusting for age, systolic pressure, diastolic pressure, BMI, smoking, drinking, TG, HDL-C, LDL-C, and FPG, SNP rs7620580 (dominant model: OR = 1.662 (95% CI 1.110--2.487), *p* = 0.014; additive model: OR = 1.636 (95% CI 1.163--2.300), *p* = 0.005; recessive model: OR = 2.686 (95% CI 1.049--6.879), *p* = 0.039) and SNP rs1708303 (dominant model: OR = 1.604 (95% CI 1.051--2.447), *p* = 0.028; additive model: OR = 1.476 (95% CI 1.020--2.135), *p* = 0.039) still showed associations with ischemic stroke.

We found an interaction between the gene variation and environment ([Table 5](#tab5){ref-type="table"}). So we also studied the association of the*KALRN* SNPs and IS under different environmental exposures, such as gender and overweight (BMI ≥ 25 kg/m^2^) ([Table 6](#tab6){ref-type="table"}). Genotypic association of SNP rs7620580 was also revealed in men before and after adjustment of covariates in the additive and dominant models. But in women, significant difference was present only after adjustment of covariates (additive model: OR = 1.804 (95% CI 1.032--3.152), *p* = 0.038, dominant model OR = 2.007 (95% CI 1.062--3.793), *p* = 0.032). The association of SNP rs1708303 and IS was present in women in the crude additive and dominant model (OR = 1.566 (95% CI 1.045--2.345), *p* = 0.030, and OR = 1.665 (95% CI 1.046--2.652), *p* = 0.032, resp.) but was lost after adjustment. No association of SNP rs1708303 and IS was found in men (*p* \> 0.05). SNP rs2289843 genotypes were associated with IS only in women after adjustment for covariates in recessive and additive model (OR = 2.186 (95% CI 1.035--4.620), *p* = 0.040, and OR = 1.658 (95% CI 1.059--2.595), *p* = 0.027, resp.). As shown in [Table 6](#tab6){ref-type="table"}, the genotype distributions of rs7620580 and rs1708303 were also different between overweight subjects and nonoverweight subjects (BMI \< 25 kg/m^2^). No genotypic association between SNP rs2289843 and IS was revealed in subjects with different BMI (*p* \> 0.05).

Thus, we concluded that rs7620580, rs1708303, and rs2289843 polymorphisms may have been associated with a risk for the development of IS among Han Chinese ([Table 3](#tab3){ref-type="table"}).

3.3. Haplotype Analysis {#sec3.3}
-----------------------

We also analyzed haplotypes using SHEsis program platform. Haplotypes were constructed in*KALRN*based on the three SNPs (rs7620580, rs2289843, and rs1708303). These 3 SNPs were in linkage disequilibrium in this study population (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Of 8 possible haplotypes, only 6 had frequencies of \>0.03 among both cases and controls and were included in our haplotype analysis ([Table 7](#tab7){ref-type="table"}). The frequencies of the A--T--G and G-T-A haplotypes in cases were significantly higher than that in controls (12.0% versus 6.0%, *p* \< 0.001 and 11.0% versus 6.9%, *p* = 0.006, resp.). The frequencies of A-T-A haplotype in cases were significantly lower than those in controls (26.2% versus 38.3%,*p* \< 0.001).

4. Discussion {#sec4}
=============

In this study, we investigated possible associations between 3 polymorphisms of the*KALRN* gene and ischemic stroke in a northern Chinese Han population. We found that SNP rs7620580, rs2289843, and rs1708303 were associated with IS and revealed that the G allele of SNP rs7620580 and G allele of SNP rs1708303 were risk factors for IS. To the best of our knowledge, this is the first study to demonstrate that these three SNPs were associated with the occurrence of ischemic stroke in Chinese population.

Age and hypertension are independent risk factors for stroke. As with other atherosclerotic diseases, stroke is a late-onset disease. Susceptibility genes can influence an early-onset of this disease when environmental factors have not had sufficient time to modify the phenotype. Several studies of the*MTHFR* and*apolipoprotein E* genes \[[@B23]\],*PDE4D* genes \[[@B24]\], and variations on chromosome 9p21 \[[@B25]\] have shown age-dependent effects. Thus, we selected place of residence and sex-matched, older, and higher blood pressure patients without stroke as controls to minimize the chances of misclassification as "stroke-free" and to exclude the impact of hypertension in the control group.

The protein encoded for by the*KALRN* gene is a complex protein with multiple catalytic, protein-protein, and protein-lipid interaction domains. It is involved in neuron morphogenesis \[[@B9], [@B10]\] and granule maturation \[[@B26], [@B27]\] and modifies synphilin-1 aggregate transport and formation \[[@B11]\]. Kalirin 7 is the most abundant isoform of kalirin in the adult brain that is nearly exclusively localized to the postsynaptic density (PSD) \[[@B28], [@B29]\] and plays an essential role in dendritic spine formation and function \[[@B30]--[@B33]\]. Kalirin 7 is also involved in ischemic signal transduction \[[@B34]\]. Nitric oxide (NO) acts as a neurotransmitter. Kalirin inhibits inducible nitric-oxide synthase (iNOS) activity \[[@B35]\] and promotes SMC migration and proliferation both in vitro and in vivo \[[@B12]\]. Kalirin\'s RhoGEF activity could plausibly augment atherogenesis by enhancing vascular SMC proliferation and migration \[[@B12], [@B36]--[@B38]\] and endothelial dysfunction \[[@B39]\].

The*KALRN* gene has been linked to schizophrenia \[[@B40], [@B41]\] and adult attention deficit-hyperactivity disorder \[[@B42]\]. Recent studies found that*KALRN* gene variations were associated with atherosclerotic diseases, such as coronary heart disease \[[@B13], [@B15]\] and stroke \[[@B43], [@B44]\], whereas Olsson et al. \[[@B45]\] found no linkage. These differences may have been due to the different ethnic groups that were studied. Different IS risk factors may also affect the results of association study. As we have shown in [Table 6](#tab6){ref-type="table"}, the associations were presented in man or thinner subjects, while they disappeared in woman or overweight ones. So the difference of our study and Olsson\'s may have been also due to different risk factors of the study subjects. Besides genetic and environmental backgrounds, differences in sample size, population admixture, and different selection criteria may explain the discrepancy, too.

The studied SNPs rs1708303 and rs2289843 were located in exons. We found that an intronic locus SNP rs7620580 was associated with IS, too. Perhaps polymorphisms in the intron region are in linkage disequilibrium with unidentified variants in regulatory elements, which affect gene transcription rates or gene expression efficiency. It is possible that an intron SNP interferes with nucleotide splicing or the formation of different spliceosomes, which might change gene structure and influence protein folding.

There were several limitations for our study. First, our subjects were selected from the rural elderly patients in Northern China during an epidemiological investigation; the conclusion may not represent populations of other genetic background. Further large-scale, randomized, long-term studies from different regions and ethnic or social background will be needed to confirm our present findings. Second, one of our selected SNPs (rs 7620580) was located in introns, the function of which was not clear. Third, because stroke is a disease that might involve multiple SNPs among multiple genes, a comprehensive analysis of the interactions between candidate genes will be more powerful than a single-locus analysis. Finally, functional studies are needed to confirm our findings from this study.

5. Conclusions {#sec5}
==============

Our results provide evidence that*KALRN* gene variations were associated with ischemic stroke in the Chinese Han population.
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###### 

Primers and probes.

  SNP                        Primers                                       Probes
  -------------------------- --------------------------------------------- ---------------------------------------
  rs7620580                  F: GGTAACTCTTGGTGACTTTGC                      TA: TTTTTTTTTTGCTTGGTAGTGGTTGCATGTGCA
  R: CATTCACCCCTTTGATCTGTG   TG: TTTTTTTTTTTTTGCTTGGTAGTGGTTGCATGTGCG      
                             TR: -P-TGTGTGCATGTGTGGACTGTCTGCTTTTTTT-FAM-   
  rs2289843                  F: CATTATGCCAAAGCAGAGAAG                      TA: GGTGACATACATCTGAAATTTGTCA
  R: TGGTGGACAGAAGGGAACAAC   TT: TTTGGTGACATACATCTGAAATTTGTCT              
                             TR: -P-GCCTAAAAAGAACAAAGATAATAAT-FAM-         
  rs1708303                  F: TTCTCTGGACTGGGGTCTACA                      TA: TTTTGAATGGAGGCAAGTCCGAGTCCGTA
  R: ACAGGACTCGTCAGCCACTTC   TG: TTTTTTTGAATGGAGGCAAGTCCGAGTCCGTG          
                             TR: -P-GCCAACCTGCAGGCCCAGCCCTCCCTTT-FAM-      

###### 

Study subjects\' characteristics.

                              Cases            Controls         *p*
  --------------------------- ---------------- ---------------- ---------
  Age (years)                 62.30 ± 9.75     69.01 ± 7.32     \<0.001
  Gender (male/female, *n*)   219/166          209/153          0.814
  Heart rate (bpm)            76.44 ± 9.66     76.29 ± 12.19    0.849
  SBP (mmHg)                  164.27 ± 23.47   189.88 ± 16.38   \<0.001
  DBP (mmHg)                  95.70 ± 14.47    102.32 ± 13.00   \<0.001
  BMI (kg/m^2^)               24.10 ± 3.71     23.29 ± 4.16     0.006
  Drinking (%)                95 (24.7%)       123 (34.0%)      0.006
  Smoking (%)                 156 (40.5%)      174 (48.1%)      0.039
  CHOL (mmol/L)               5.35 ± 1.05      5.40 ± 1.03      0.499
  TG (mmol/L)                 1.89 ± 1.47      1.62 ± 1.17      0.006
  LDL-C (mmol/L)              3.08 ± 0.75      2.85 ± 0.71      \<0.001
  HDL-C (mmol/L)              1.35 ± 0.33      1.48 ± 0.32      \<0.001
  FPG (mmol/L)                6.25 ± 2.22      5.93 ± 1.96      0.035

Note: *n*, number; SBP, systolic pressure; DBP, diastolic pressure; BMI, body mass index; TG, triglyceride; CHOL, total cholesterol; HDL-C, high density lipid cholesterol; LDL-C, low density lipid cholesterol; FPG, fasting plasma glucose.

###### 

Genotype distributions and detailed association results.

  Genotype    IS (*n*)   Control (*n*)   OR (95% CI)                *p*         OR (95% CI)^*∗*^           *p* ^*∗*^
  ----------- ---------- --------------- -------------------------- ----------- -------------------------- -----------
  rs7620580                                                                                                 
  AA          199        228             1.000                                  1.000                       
  AG          166        122             **1.559 (1.153--2.107)**   **0.004**   **1.534 (1.011--2.328)**   **0.045**
  GG          20         12              1.910 (0.911--4.004)       0.087       **3.195 (1.228--8.312)**   **0.017**
  Recessive                              1.598 (0.770--3.318)       0.208       **2.686 (1.049--6.879)**   **0.039**
  Additive                               **1.490 (1.157--1.919)**   **0.002**   **1.636 (1.163--2.300)**   **0.005**
  Dominant                               **1.590 (1.187--2.130)**   **0.002**   **1.662 (1.110--2.487)**   **0.014**
  rs2289843                                                                                                 
  TT          101        107             1.000                                  1.000                       
  TA          195        181             1.141 (0.813--1.602)       0.445       1.291 (0.809--2.059)       0.285
  AA          89         74              1.274 (0.845--1.922)       0.248       1.402 (0.807--2.434)       0.231
  Recessive                              1.170 (0.826--1.658)       0.377       1.197 (0.748--1.914)       0.453
  Additive                               1.130 (0.920--1.386)       0.243       1.189 (0.903--1.566)       0.216
  Dominant                               1.180 (0.857--1.625)       0.311       1.326 (0.856--2.053)       0.206
  rs1708303                                                                                                 
  AA          241        260             1.000                                  1.000                       
  AG          132        94              **1.515 (1.103--2.081)**   **0.010**   **1.610 (1.040--2.490)**   **0.033**
  GG          12         8               1.618 (0.650--4.027)       0.301       1.550 (0.484--4.969)       0.461
  Recessive                              1.424 (0.575--3.524)       0.445       1.338 (0.421--4.250)       0.622
  Additive                               **1.438 (1.092--1.892)**   **0.010**   **1.476 (1.020--2.135)**   **0.039**
  Dominant                               **1.523 (1.119--2.073)**   **0.007**   **1.604 (1.051--2.447)**   **0.028**

 ^*∗*^adjusted for age, SBP, DBP, FPG, TG, HDL, LDL, smoking, drinking, and BMI.

###### 

SNP allele frequencies in cases and controls.

  Allele      Cases (*n*)   Controls (*n*)   OR (95% CI)                *p*         HWE P in controls
  ----------- ------------- ---------------- -------------------------- ----------- -------------------
  rs7620580                                                                         0.37
  A allele    564           578              1                          ---          
  G allele    206           146              **1.446 (1.136--1.841)**   **0.003**    
  rs2289843                                                                         0.87
  T allele    397           395              1                          ---          
  A allele    373           329              1.128 (0.920--1.382)       0.246        
  rs1708303                                                                         0.88
  A allele    614           614              1                          ---          
  G allele    156           110              **1.418 (1.084--1.855)**   **0.011**    

###### 

Interaction of three SNPs and environmental risk factors on IS.

  ----------- ------------ ---------- -------------------------- -------------------------- -----------
  Genotype    Gender       IS (*n*)   Control (*n*)              OR (95% CI)                *p*

                                                                                            

  rs7620580                                                                                  

  AA          M            109        133                        1                           

  F           90           95         1.156 (0.788--1.697)       0.459                      

  AA + AG     M            110        76                         **1.766 (1.200--2.600)**   **0.004**

  F           76           58         0.783 (0.434--1.415)       0.418                      

  rs2289843                                                                                  

  TT + TA     M            166        158                        1                           

  F           130          130        1.171 (0.822--1.668)       0.383                      

  AA          M            53         51                         0.954 (0.591--1.542)       0.849

  F           36           23         1.736 (0.799--3.770)       0.163                      

  rs1708303                                                                                  

  AA          M            143        152                        1                           

  F           98           108        1.212 (0.823--1.784)       0.331                      

  AA + AG\    M            76         57                         1.444 (0.928--2.247)       0.104

  F           68           45         1.182 (0.607--2.303)       0.623                      

                                                                                            

  Genotype    Overweight   IS (*n*)   Control (*n*)              OR (95% CI)                *p*

                                                                                            

  rs7620580                                                                                  

  AA          Null         129        176                                                    

  Yes         69           52         **1.839 (1.201--2.816)**   **0.005**                  

  AA + AG     Null         121        97                         **1.714 (1.206--2.437)**   **0.003**

  Yes         64           37         0.760 (0.399--1.450)       0.406                      

  rs2289843                                                                                  

  TT + TA     Null         197        220                                                    

  Yes         97           68         1.601 (1.112--2.306)       0.011                      

  AA          Null         53         53                         1.080 (0.703--1.660)       0.725

  Yes         36           21         1.113 (0.523--2.368)       0.782                      

  rs1708303                                                                                  

  AA          Null         152        193                                                    

  Yes         88           67         **1.679 (1.145--2.461)**   **0.008**                  

  AA + AG\    Null         98         80                         **1.534 (1.065--2.210)**   **0.022**

  Yes         45           22         1.015 (0.503--2.051)       0.966                      

                                                                                            

  Genotype    Smoking      IS (*n*)   Control (*n*)              OR (95% CI)                *p*

                                                                                            

  rs7620580                                                                                  

  AA          Null         117        117                                                    

  Yes         82           111        0.739 (0.503--1.084)       0.122                      

  AA + AG     Null         112        71                         **1.577 (1.065--2.336)**   **0.023**

  Yes         74           63         1.008 (0.559--1.819)       0.979                      

  rs2289843                                                                                  

  TT + TA     Null         177        159                                                    

  Yes         119          129        1.062 (0.612--1.842)       0.832                      

  AA          Null         52         29                         1.486 (0.972--2.272)       0.068

  Yes         37           45         0.599 (0.313--1.145)       0.121                      

  rs1708303                                                                                  

  AA          Null         145        133                                                    

  Yes         96           127        **0.693 (0.486--0.988)**   **0.043**                  

  AA + AG\    Null         84         55                         1.401 (0.926--2.118)       0.11

  Yes         60           47         1.206 (0.647--2.246)       0.556                      

                                                                                            

  Genotype    Drinking     IS (*n*)   Control (*n*)              OR (95% CI)                *p*

                                                                                            

  rs7620580                                                                                  

  AA          Null         146        153                                                    

  Yes         53           75         0.741 (0.487--1.125)       0.159                      

  AA + AG     Null         144        86                         **1.755 (1.236--2.491)**   **0.002**

  Yes         42           48         0.706 (0.370--1.347)       0.291                      

  rs2289843                                                                                  

  TT + TA     Null         224        194                                                    

  Yes         72           94         0.777 (0.424--1.425)       0.415                      

  AA          Null         66         45                         1.286 (0.879--1.880)       0.195

  Yes         23           29         0.757 (0.371--1.542)       0.443                      

  rs1708303                                                                                  

  AA          Null         182        168                                                    

  yes         59           92         **0.592 (0.401--0.873)**   **0.008**                  

  AA + AG\    null         108        71                         1.404 (0.974--2.024)       0.069

  yes         36           31         1.29 (0.649--2.562)        0.468                      
  ----------- ------------ ---------- -------------------------- -------------------------- -----------

###### 

Analysis of kalirin genotypic association with IS in subgroups.

  ------------- ------------------------------- ------------------------------ ------------------------------- -------------------------------
  *rs7620580*                                                                                                  
                                                                                                               
  Gender                                                                                                       
                                                                                                               
  Genotype      Woman                           Man                                                            
  OR (95% CI)   OR (95% CI)^*∗*^                OR (95% CI)                    OR (95% CI)^*∗∗*^               
                                                                                                               
  AG            1.368 (0.866--2.162)            **1.988 (1.035--3.816)** ^▲^   **1.723 (1.154--2.572)** ^▲▲^   **1.776 (1.096--2.877)**
  GG            1.583 (0.433--5.796)            2.236 (0.410--12.201)          2.135 (0.864--5.277)            **3.661 (1.215--11.036)**
  Recessive     1.397 (0.387--5.048)            1.682 (0.319--8.876)           1.716 (0.704--4.179)            2.895 (0.982--8.541)
  Additive      1.334 (0.896--1.987)            **1.804 (1.032--3.152)** ^▲^   **1.608 (1.158--2.233)** ^▲▲^   **1.832 (1.235--2.719)** ^▲▲^
  Dominant      1.383 (0.884--2.163)            **2.007 (1.062--3.793)** ^▲^   **1.766 (1.200--2.600)** ^▲▲^   **1.923 (1.206--3.067)** ^▲▲^
                                                                                                               
  BMI                                                                                                          
                                                                                                               
  Genotype      BMI \< 25 kg/m^2^               BMI ≥ 25 kg/m^2^                                               
  OR (95% CI)   OR (95% CI)^*∗∗∗*^              OR (95% CI)                    OR (95% CI)^*∗∗∗∗*^             
                                                                                                               
  AA            1                               1                              1                               1
  AG            **1.658 (1.157--2.377)** ^▲▲^   1.598 (0.999--2.557)           1.302 (0.744--2.278)            1.966 (0.887--4.357)
  GG            2.200 (0.866--5.462)            3.055 (0.918--10.166)          1.319 (0.367--4.744)            4.130 (0.858--19.874)
  Recessive     1.802 (0.734--4.422)            2.565 (0.781--8.424)           1.181 (0.335--4.157)            3.105 (0.681--14.156)
  Additive      **1.593 (1.175--2.160)** ^▲▲^   **1.651 (1.112--2.451)** ^▲^   1.236 (0.780--1.959)            **1.999 (1.077--3.711)** ^▲^
  Dominant      **1.703 (1.200--2.416)** ^▲▲^   **1.699 (1.077--2.680)** ^▲^   1.304 (0.758--2.241)            **2.188 (1.019--4.700)** ^▲^
                                                                                                               
  *rs2289843*                                                                                                  
                                                                                                               
  Gender                                                                                                       
                                                                                                               
  Genotype      Woman                           Man                                                            
  OR (95% CI)   OR (95% CI)^*∗*^                OR (95% CI)                    OR (95% CI)^*∗∗*^               
                                                                                                               
  TT            1                               1                              1                               1
  TA            1.070 (0.643--1.779)            1.443 (0.687--3.033)           1.203 (0.763--1.895)            1.421 (0.825--2.446)
  AA            1.635 (0.842--3.175)            **2.782 (1.134--6.826)** ^▲^   1.113 (0.656--1.891)            1.208 (0.645--2.264)
  Recessive     1.565 (0.879--2.787)            **2.186 (1.035--4.620)** ^▲^   0.989 (0.636--1.539)            0.970 (0.573--1.642)
  Additive      1.250 (0.903--1.730)            **1.658 (1.059--2.595)** ^▲^   1.059 (0.813--1.380)            1.108 (0.810--1.515)
  Dominant      1.192 (0.734--1.936)            1.765 (0.872--3.570)           1.172 (0.765--1.796)            1.344 (0.810--2.231)
                                                                                                               
  BMI                                                                                                          
                                                                                                               
  Genotype      BMI \< 25kg/m^2^                BMI ≥ 25 kg/m^2^                                               
  OR (95% CI)   OR (95% CI)^*∗∗∗*^              OR (95% CI)                    OR (95% CI)^*∗∗∗∗*^             
                                                                                                               
  TT            1                               1                              1                               1
  TA            1.033 (0.692--1.541)            1.134 (0.678--1.897)           1.490 (0.782--2.839)            1.889 (0.733--4.866)
  AA            1.129 (0.686--1.858)            1.370 (0.723--2.596)           1.548 (0.737--3.252)            1.569 (0.581--4.241)
  Recessive     1.106 (0.722--1.693)            1.266 (0.730--2.197)           1.202 (0.646--2.236)            1.071 (0.474--2.420)
  Additive      1.060 (0.827--1.357)            1.167 (0.850--1.602)           1.250 (0.860--1.817)            1.238 (0.754--2.034)
  Dominant      1.059 (0.724--1.548)            1.197 (0.736--1.947)           1.510 (0.818--2.756)            1.741 (0.740--4.097)
                                                                                                               
  *rs1708303*                                                                                                  
                                                                                                               
  Gender                                                                                                       
                                                                                                               
  Genotype      Woman                           Man                                                            
  OR (95% CI)   OR (95% CI)^*∗*^                OR (95% CI)                    OR (95% CI)^*∗∗*^               
                                                                                                               
  AA            1                               1                              1                               1
  AG            1.613 (0.996--2.612)            1.663 (0.846--3.272)           1.444 (0.947--2.202)            1.497 (0.901--2.487)
  GG            2.204 (0.644--7.548)            1.191 (0.236--6.015)           1.063 (0.261--4.330)            0.875 (0.168--4.564)
  Recessive     1.886 (0.556--6.394)            1.020 (0.205--5.072)           0.953 (0.235--3.863)            0.778 (0.150--4.034)
  Additive      **1.566 (1.045--2.345)** ^▲^    1.414 (0.809--2.470)           1.332 (0.914--1,941)            1.331 (0.848--2.090)
  Dominant      **1.665 (1.046--2.652)** ^▲^    1.602 (0.837--3.068)           1.417 (0.938--2.141)            1.447 (0.881--2.374)
                                                                                                               
  BMI                                                                                                          
                                                                                                               
  Genotype      BMI \< 25 kg/m^2^               BMI ≥ 25 kg/m^2^                                               
  OR (95% CI)   OR (95% CI)^*∗∗∗*^              OR (95% CI)                    OR (95% CI)^*∗∗∗∗*^             
                                                                                                               
  AA            1                               1                              1                               1
  AG            **1.590 (1.094--2.309)** ^▲^    1.368 (0.841--2.227)           1.450 (0.783--2.686)            **2.435 (1.003--5.912)** ^▲^
  GG            1.261 (0.433--3.674)            0.969 (0.248--3.781)           3.807 (0.434--33.355)           2.035 (0.164--25.291)
  Recessive     1.086 (0.375--3.140)            0.880 (0.227--3.417)           3.437 (0.395--29.930)           1.651 (0.136--20.089)
  Additive      **1.431 (1.036--1.978)** ^▲^    1.232 (0.813--1.867)           1.564 (0.912--2.683)            2.095 (0.962--4.562)
  Dominant      **1.561 (1.086--2.244)** ^▲^    1.329 (0.829--2.131)           1.557 (0.854--2.840)            **2.397 (1.018--5.644)** ^▲^
  ------------- ------------------------------- ------------------------------ ------------------------------- -------------------------------

 ^*∗*^adjusted for age, SBP, and drinking history in men;  ^*∗∗*^adjusted for age, SBP, LDL-C, and smoking history in women;  ^*∗∗∗*^adjusted for age, SBP, LDL-C, and smoking history in BMI \< 25 kg/m2;  ^*∗∗∗∗*^adjusted for age, SBP, LDL-C, and smoking history in BMI ≥ 25 kg/m2; ^▲^*p* \< 0.05, ^▲▲^*p* \< 0.01.

###### 

Haplotype analysis in cases and controls.

  Haplotype   Cases (freq.)   Controls (freq.)   OR (95% CI)                *p*
  ----------- --------------- ------------------ -------------------------- -------------
  A-T-A       202 (0.262)     281 (0.388)        **0.557 (0.446\~0.695)**   **\<0.001**
  A-T-G       92 (0.120)      44 (0.060)         **2.138 (1.467\~3.115)**   **\<0.001**
  A-A-A       242 (0.315)     219 (0.303)        1.064 (0.852\~1.328)       0.585
  A-A-G       28 (0.036)      35 (0.048)         0.745 (0.447\~1.242)       0.257
  G-T-A       84 (0.110)      50 (0.069)         **1.661 (1.152\~2.395)**   **0.006**
  G-A-A       85 (0.111)      64 (0.088)         1.295 (0.919\~1.823)       0.139

All haplotypes with a frequency of \< 0.03 were ignored for this analysis.

[^1]: Academic Editor: Maria Barbolina
